Relapse of Wilms' tumor 13 years after original diagnosis

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 5, 2005, Pages 293-294

  Gibson, Paul J ^a   Vadeboncoeur, Christina M ^b   Johnston, Donna L ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ADOLESCENT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CASE REPORT; CHROMOSOME 1; CYTOGENETICS; FEMALE; FOLLOW UP; HUMAN; ISOCHROMOSOME; LETTER; LUNG METASTASIS; NEPHRECTOMY; NEPHROBLASTOMA; PRIORITY JOURNAL; RECURRENCE RISK; THORAX RADIOGRAPHY;

ADOLESCENT; CHROMOSOME MAPPING; COMBINED MODALITY THERAPY; FEMALE; HEMOTHORAX; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; NEOPLASMS, SECOND PRIMARY; RADIOGRAPHY, THORACIC; RECURRENCE; WILMS TUMOR;

EID: 18944406181     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000164864.62899.55     Document Type: Letter

References (15)

1. Dome JS, Liu T, Drasin M, et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude's Children Research Hospital. J Pediatr Hematol Oncol. 2002;24:192-I98.
2. Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 1998;16:237-245.
3. Tournade MF, Com-Nougue C, Voute PA, et al. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor. J Clin Oncol. 1993;11:1014-1023.
4. Gallego-Melcon S, Sanchez de Toledo J, Doste D, et al. Late recurrent metastasis in Wilms' tumour. Med Pediatr Oncol. 1994;23:158-161.
5. Mikraki V, Yiannoulopoulos G, Moschovi M, et al. Late local recurrence of Wilms' tumor. Med Pediatr Oncol. 1996;26:71.
6. Green DM, Donckerwolcke R, Evans AE, et al. Late effects of treatment for Wilms tumor. Hematol Oncol Clin North Am. 1995;9:1317-1327.
7. Meadows AT, Baum E, Fossati-Bellani F, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol. 1985;3:532-538.
8. Carli M, Frascella E, Tournade MF, et al. Second malignant neoplasms in patients treated on SIOP Wilms tumor studies and trials 1, 2, 5, and 6. Med Pediatr Oncol. 1997;29:239-244.
9. Breslow NE, Takashima JR, Whitton JA, et al. Second malignant neoplasms following treatment for Wilms' tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 1995;13:1851-1859.
10. Douglass EC, Look AT, Webber B, et al. Hyperdiploidy and chromosomal rearrangements deline the anaplastic variant of Wilms' tumor. J Clin Oncol. 1986;4:975-981.
11. Grundy PE, Telzerow PE, Breslow N, et al. Loss of heterozygosity for chromosome 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res. 1994;54:2331-2333.
12. Klamt B, Schulze M, Thate C, et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters. Genes Chromosomes Cancer. 1998;22:287-294.
13. Hing S, Lu YJ, Summersgill B, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumor 2. Am J Pathol. 2001;158:393-398.
14. Lu YJ, Hing S, Williams R, et al. Chromosome 1q expression profiling and relapse in Wilms' tumor. Lancet. 2002;360:385-386.
15. Bown N, Cotterill SJ, Roberst P, et al. Cytogenetic abnormalities and clinical outcome in Wilms tumor: A study by the U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol. 2002;38:11-21.